A clinical trial has found that the medication omalizumab, marketed as Xolair, treated multi-food allergy more effectively than oral immunotherapy (OIT) in people with allergic reactions to very small ...

The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

Additionally, preliminary results from Stage 3 of the OUtMATCH study provide early data on introducing allergenic foods into a patient’s diet after stopping Xolair. These findings were featured as ...

The high rate of allergic reactions and other intolerable side effects of oral immunotherapy in the NIH-funded trial explained the superiority of omalizumab.

New research shows home-measured peanut oral immunotherapy boosts peanut tolerance in allergic children, with long-term benefits.

Stage 2 of the NIH-sponsored phase 3 OUtMATCH trial—the first head-to-head study of Xolair versus OIT—met its primary endpoint, Roche's Genentech said in a Sunday press release. The trial ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...